Want to see BBNX full AI Analyst Report?
BBNX Stock Chart & Stats
$15.85
$0.14(0.88%)
At close: 4:00 PM EDT
$15.85
$0.14(0.88%)
Day’s Range― - ―
52-Week Range$8.80 - $32.71
Previous Close$15.99
Volume845.79K
Average Volume (3M)1.02M
Market Cap
$577.22M
Enterprise Value$523.95
Total Cash (Recent Filing)$180.49M
Total Debt (Recent Filing)$6.51M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 03, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding44,989,690
10 Day Avg. Volume1,123,658
30 Day Avg. Volume1,018,382
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio-21.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.11Price Target Upside33.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$133.49M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Recurring Pharmacy TractionSustained ~38% YoY revenue growth and growing pharmacy reimbursement mix create a more predictable, recurring revenue base. Pharmacy channel adoption improves retention and LTV, supporting scaling economics and allowing demand visibility for manufacturing and commercial investment over the next 2–6 months.
Improving Gross MarginsMaterial year‑over‑year margin expansion to ~59% indicates unit economics are improving. Durable drivers—lower warranty rates from upgraded screens and manufacturing scale readiness—suggest margin sustainability as volumes rise, supporting eventual operating leverage as sales scale further.
Healthy Balance Sheet And Low LeverageA cash balance around $225M combined with very low reported debt provides a multi‑quarter runway to fund commercialization, R&D and FDA activities without immediate refinancing. Conservative balance-sheet positioning reduces near-term liquidity risk while the company pursues product launches and commercialization scale.
Bears Say
Persistent Negative Free Cash FlowSustained negative operating and free cash flow means the business remains cash‑consumptive while scaling. Until operating cash flow turns positive, the company may need external capital or dilute shareholders; this constrains long‑term financial optionality and elevates execution risk over the medium term.
Operating Expenses Exceed RevenueOpEx outpacing sales highlights negative operating leverage: high fixed investment in sales and R&D must be absorbed by future revenue. If revenue cadence or reimbursement adoption slows, persistent OpEx growth could delay profitability and increase the need for capital, pressuring long‑term margins.
Regulatory And Product Timing RiskOngoing FDA remediation and reliance on 510(k) clearances for Mint and indication expansions create durable execution risk. Regulatory delays or additional agency requirements can postpone commercial rollouts, extend cash burn, and reduce near‑term revenue visibility despite manufacturing readiness.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.80 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $577.22M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Nov 03, 2026 which is in 93 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Jul 29, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.581 by $0.051.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,989,690 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.581. Following the earnings report the stock price went down -5.933%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.11 (33.20% Upside)
$21.11 (33.20% Upside)
Blogger Sentiment
Neutral
BBNX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 310.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $472.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.39%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call emphasized strong commercial momentum (38% YoY revenue growth), meaningful year‑over‑year margin improvement, a healthy cash position (~$225M), and tangible progress across the innovation pipeline (Mint manufacturing readiness, Type 2 pivotal trial alignment, bihormonal iteration plan). Offsetting factors include elevated operating expenses (37% YoY), Q2 operating expenses exceeding revenue, ongoing FDA remediation work, some near‑term revenue volatility from pharmacy stocking dynamics, and timing/clearance risks for new products. Taken together, the positives around growth, margin expansion, capital runway, and concrete product progress modestly outweigh the near‑term cost and regulatory risks.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$21.11
▲(33.20% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
2.79% Insiders
22.08% Mutual Funds
0.39% Other Institutional Investors
65.04% Public Companies and
Individual Investors